In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates

Infezioni in Medicina

Volumn 17, Issue 4, 2009, Pages 236-239

  Ricciardi, Rosanna ^a   Ricciardi, Anna Maria ^a   Danzi, Gaetano ^a  

^a San Giuseppe Moscati Hospital   (Italy)

Author keywords

Acinetobacter baumannii; Multidrug resistant; Tigecycline

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 77649300642     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Henwood C.J., Gatward T., Warner M., et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation to tigecycline (GAR-936). J. Antimicrob. Chemother. 49: 479-487, 2002.
2. Hoban D., Bouchillon S., Johnson B., Johnson J., Dowzicky M. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. 52: 215-227, 2005.
3. Insa R., Cercenado E., Goyanes M.J., Morente A., Bouza E. In vitro activity to tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 59: 583-585, 2007.
4. Moland E., Craft D., Hong S., Hachmeister L., Sayed S., Thomson k. In vitro activity of Tigecycline against Multidrug-resistant Acinetobacter baumannii and selection of Tigecycline-Amikacin synergy. Antimicrob. Agents Chemother. 52 (8): 2940-2942, 2008.
5. Jones C. H., Peterson P.J. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today. 41: 637-659, 2005.
6. Longo B. AP., Luzzi I., Placanica S., et al. An outbreak of Acinetobacter baumannii in an intensive care unit: epidemiological and molecular findings. J. Hosp. Infect. 64 (3): 303-305, 2006.
7. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: M100-S16, 16th informational supplement, 2006. Wayne, PA.
8. Bolmstrom A., Karlsson A., Engelhardt A., et al. Validation and reproducibility assessment of Tigecycline MIC. Determinations by Etest. J. Clin. Microbiol. 2474-2479, 2007.
9. Pachon-Ibanez M.E., Jimenez-Mejias M.E., Pichardo C., Llanos A.C., Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48: 4479-4481, 2004.
10. Fritsche T.R., Strabala P.A., Sader H.S., Dowzicky M.J., Jones R.N. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis. 52: 209-213, 2005.
11. Hawkey P., Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin. Microbiol. Infect. 13: 354-362, 2007.
12. Eser O.K., Ergin A., Tunckanat F., Hasscelik G. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp. New Microbiol. 31: 535-542, 2008.
13. Bou G., Cervero G., Dominquez M.A., Quereda C., Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenems-hydrolyzing enzyme: high level carbapenems resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. 38: 3299-3305, 2000.
14. Richet H.M., Mohammed J., McDonald L.C., Jarvis W.R. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg. Infect. Dis. 7: 319-322, 2001.